LC-MS/MS identification of the principal in vitro and in vivo phase i metabolites of the novel thiosemicarbazone anti-cancer drug, Bp4eT

Analytical and Bioanalytical Chemistry

Volumn 403, Issue 1, 2012, Pages 309-321

  Stariat, Ján ^a   Šesták, Vít ^a   Vávrová, Kateřina ^a   Nobilis, Milan ^a   Kollárová, Zuzana ^a   Klimeš, Jiří ^a   Kalinowski, Danuta S ^b   Richardson, Des R ^a,b   Kovaříková, Petra ^a  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

2 Benzoylpyridine 4 ethyl 3 thiosemicarbazone; Anti cancer; Anti tumor chemotherapeutic; Bp4eT; LC MS

Indexed keywords

2-BENZOYLPYRIDINE-4-ETHYL-3-THIOSEMICARBAZONE; ANTI-CANCER; ANTI-TUMORS; BP4ET; LC-MS;

BIOMOLECULES; DISEASES; HYDROGEN PEROXIDE; LEAD COMPOUNDS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLITES; PHYSIOLOGY;

METABOLISM;

2 BENZOYLPYRIDINE 4 ETHYL 3 THIOSEMICARBAZONE; 2-BENZOYLPYRIDINE 4-ETHYL-3-THIOSEMICARBAZONE; ANTINEOPLASTIC AGENT; THIOSEMICARBAZONE DERIVATIVE;

ANIMAL; ARTICLE; HUMAN; IN VITRO STUDY; INFRARED SPECTROPHOTOMETRY; LIQUID CHROMATOGRAPHY; MALE; METABOLISM; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; RAT; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY;

ANIMALS; ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, LIQUID; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; RATS; SOLID PHASE EXTRACTION; SPECTROPHOTOMETRY, INFRARED; TANDEM MASS SPECTROMETRY; THIOSEMICARBAZONES;

MAMMALIA; RATTUS;

EID: 84858748865     PISSN: 16182642     EISSN: 16182650     Source Type: Journal    
DOI: 10.1007/s00216-012-5766-4     Document Type: Article

References (39)

1. GLOBOCAN 2008 (IARC) Section of Cancer Information WHO http://www.who.int/mediacentre/factsheets/fs297/en/. Accessed 19 Oct 2011
2. Y Yu DS Kalinowski Z Kovacevic AR Siafakas PJ Jansson C Stefani DB Lovejoy PC Sharpe PV Bernhardt DR Richardson 2009 Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors J Med Chem 52 5271 5294 10.1021/jm900552r 1:CAS:528: DC%2BD1MXosVGjs7g%3D
3. DR Richardson DS Kalinowski S Lau PJ Jansson DB Lovejoy 2009 Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents Biochim Biophys Acta 1790 702 717 10.1016/j.bbagen.2008.04.003 1:CAS:528:DC%2BD1MXnt1yjurg%3D
4. JL Buss FM Torti SV Torti 2003 The role of iron chelation in cancer therapy Curr Med Chem 10 1021 1034 10.2174/0929867033457638 1:CAS:528: DC%2BD3sXjs1yjtb8%3D
5. JL Buss BT Greene J Turner FM Torti SV Torti 2004 Iron chelators in cancer chemotherapy Curr Top Med Chem 4 1623 1635 10.2174/1568026043387269 1:CAS:528:DC%2BD2cXhtVKmsbvJ
6. M Whitnall J Howard P Ponka DR Richardson 2006 A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics Proc Natl Acad Sci U S A 103 14901 14906 10.1073/pnas. 0604979103 1:CAS:528:DC%2BD28XhtVyhu7jL
7. DA Green WE Antholine SJ Wong DR Richardson CR Chitambar 2001 Inhibition of malignant cell growth by 311, a novel iron chelator of the pyridoxal isonicotinoyl hydrazone class: effect on the R2 subunit of ribonucleotide reductase Clin Cancer Res 7 3574 3579 1:CAS:528:DC%2BD3MXptFaisLg%3D
8. B Ma BC Goh EH Tan KC Lam R Soo SS Leong LZ Wang F Mo AT Chan B Zee T Mok 2008 A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells Invest New Drugs 26 169 173 10.1007/s10637-007-9085-0 1:CAS:528: DC%2BD1cXivFKnsL0%3D
9. CM Nutting CM van Herpen AB Miah SA Bhide JP Machiels J Buter C Kelly D de Raucourt KJ Harrington 2009 Phase II study of 3-AP Triapine in patients with recurrent or metastatic head and neck squamous cell carcinoma Ann Oncol 20 1275 1279 10.1093/annonc/mdn775 1:STN:280:DC%2BD1MvivFalsg%3D%3D
10. DS Kalinowski Y Yu PC Sharpe M Islam YT Liao DB Lovejoy N Kumar PV Bernhardt DR Richardson 2007 Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents J Med Chem 50 3716 3729 10.1021/jm070445z 1:CAS:528:DC%2BD2sXns1Churw%3D
11. DS Kalinowski PC Sharpe PV Bernhardt DR Richardson 2007 Design, synthesis, and characterization of new iron chelators with anti-proliferative activity: structure-activity relationships of novel thiohydrazone analogues J Med Chem 50 6212 6225 10.1021/jm070839q 1:CAS:528:DC%2BD2sXht1arsLbP
12. Yu Y, Rahmanto YS, Richardson D (2011) Bp44mT: an orally-active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy. Br J Pharmacol. doi: 10.1111/j.1476-5381.2011.01526.x
13. Z Kovacevic S Chikhani DB Lovejoy DR Richardson 2011 Novel thiosemicarbazone iron chelators induce up-regulation and phosphorylation of the metastasis suppressor N-myc down-stream regulated gene 1: a new strategy for the treatment of pancreatic cancer Mol Pharmacol 80 598 609 10.1124/mol.111. 073627 1:CAS:528:DC%2BC3MXhs1ansbvL
14. J Stariat P Kovarikova J Klimes DS Kalinowski DR Richardson 2010 Development of an LC-MS/MS method for analysis of interconvertible Z/E isomers of the novel anticancer agent, Bp4eT Anal Bioanal Chem 397 161 171 10.1007/s00216-009-3448-7 1:CAS:528:DC%2BC3cXhtl2ntL4%3D
15. C Chen FJ Gonzalez JR Idle 2007 LC-MS-based metabolomics in drug metabolism Drug Metab Rev 39 581 597 10.1080/03602530701497804 1:CAS:528:DC%2BD2sXhtVSktL7L
16. L Jia X Liu 2007 The conduct of drug metabolism studies considered good practice (II): in vitro experiments Curr Drug Metab 8 822 829 10.2174/138920007782798207 1:CAS:528:DC%2BD2sXhsVahtrrP
17. S Wadler D Makower C Clairmont P Lambert K Fehn M Sznol 2004 Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion J Clin Oncol 22 1553 1563 10.1200/JCO.2004.07. 158 1:CAS:528:DC%2BD2cXpsVWmur4%3D
18. J Murren M Modiano C Clairmont P Lambert N Savaraj T Doyle M Sznol 2003 Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors Clin Cancer Res 9 4092 4100 1:CAS:528:DC%2BD3sXns1OjtLs%3D
19. M Holcapek L Kolarova M Nobilis 2008 High-performance liquid chromatography-tandem mass spectrometry in the identification and determination of phase I and phase II drug metabolites Anal Bioanal Chem 391 59 78 10.1007/s00216-008-1962-7 1:CAS:528:DC%2BD1cXkvFClurw%3D
20. X Liu L Jia 2007 The conduct of drug metabolism studies considered good practice (I): analytical systems and in vivo studies Curr Drug Metab 8 815 821 10.2174/138920007782798153 1:CAS:528:DC%2BD2sXhsVahtrrO
21. DB Lovejoy DR Richardson 2002 Novel "hybrid" iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate selective antiproliferative activity against tumor cells Blood 100 666 676 10.1182/blood.V100.2.666 1:CAS:528:DC%2BD38XlsVWgtbs%3D
22. M Nobilis T Jira M Lisa M Holcapek B Szotakova J Lamka L Skalova 2007 Achiral and chiral high-performance liquid chromatographic determination of flubendazole and its metabolites in biomatrices using UV photodiode-array and mass spectrometric detection J Chromatogr A 1149 112 120 10.1016/j.chroma.2007. 01.013 1:CAS:528:DC%2BD2sXkslKkurg%3D
23. M Nobilis Z Vybíralová Z Szotáková Z Sládková M Kuneš Z Svoboda 2011 High-performance liquid chromatographic determination of tiapride and its phase I metabolite in blood plasma using tandem UV photodiode-array and fluorescence detection J Chromatogr B 879 3845 3852 10.1016/j.jchromb.2011.10.032 1:CAS:528:DC%2BC3MXhsFOgtL3K
24. PK Smith RI Krohn GT Hermanson AKI Mallia FH Gartner MD Provenzano EK Fujimoto NM Goeke BJ Olson DC Klenk 1985 Measurement of protein using bicinchoninic acid Anal Biochem 150 76 85 10.1016/0003-2697(85)90442-7 1:CAS:528:DyaL2MXlsFKksL0%3D
25. J Stariat P Kovarikova J Klimes DB Lovejoy DS Kalinowski DR Richardson 2009 HPLC methods for determination of two novel thiosemicarbazone anti-cancer drugs (N4mT and Dp44mT) in plasma and their application to in vitro plasma stability of these agents J Chromatogr B 877 316 322 10.1016/j.jchromb.2008.11. 044 1:CAS:528:DC%2BD1MXksVGisw%3D%3D
26. DM Peiris W Lam S Michael R Ramanathan 2004 Distinguishing N-oxide and hydroxyl compounds: impact of heated capillary/heated ion transfer tube in inducing atmospheric pressure ionization source decompositions J Mass Spectrom 39 600 606 10.1002/jms.623 1:CAS:528:DC%2BD2cXls1art78%3D
27. S Ma SK Chowdhury KB Alton 2005 Thermally induced N-to-O rearrangement of tert-N-oxides in atmospheric pressure chemical ionization and atmospheric pressure photoionization mass spectrometry: differentiation of N-oxidation from hydroxylation and potential determination of N-oxidation site Anal Chem 77 3676 3682 10.1021/ac048203j 1:CAS:528:DC%2BD2MXjsFaiu74%3D
28. A Corsaro V Pistara 1998 Conversion of the thiocarbonyl group into the carbonyl group Tetrahedron 54 15027 15062 10.1016/S0040-4020(98)00880-1 1:CAS:528:DyaK1cXnvFWmur0%3D
29. MU Ali HM Meshram MG Paranjpe 1985 Raney-nickel desulfuration of 1-substituted-thioureas and 1,3-disubstituted-thioureas J Indian Chem Soc 62 666 669 1:CAS:528:DyaL28XlvFWmsbs%3D
30. W Walter KP Ruess 1969 Oxidative products of thiocarboxylic acid amides. XXIV. Preparation of S, S-di- and S, S, S-trioxides of trisubstituted thioureas and a new preparative method for trisubstituted formamidines Chem Ber 102 2640 2650 10.1002/cber.19691020820 1:CAS:528:DyaF1MXkvFSqtLg%3D
31. GJ Stevens K Hitchcock KY Wang GM Coppola RW Versace JA Chin M Shapiro S Suwanrumpha BLK Mangold 1997 In vitro metabolism of N-(5-chloro-2-methylphenyl)- N'-(2-methylpropyl)thiourea: species comparison and identification of a novel thiocarbamide-glutathione adduct Chem Res Toxicol 10 733 741 10.1021/tx9700230 1:CAS:528:DyaK2sXktVSis74%3D
32. DR Richardson PC Sharpe DB Lovejoy D Senaratne DS Kalinowski M Islam PV Bernhardt 2006 Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity J Med Chem 49 6510 6521 10.1021/jm0606342 1:CAS:528:DC%2BD28XhtVWhsL%2FK
33. H Rapoport RM Bonner 1950 The preparation of some tetrasubstituted amidrazones J Am Chem Soc 72 2783 2784 10.1021/ja01162a523 1:CAS:528: DyaG3cXlt1ShtQ%3D%3D
34. RF Smith DS Johnson RA Abgott MJ Madden 1973 Amidrazones.2. Tautomerism and alkylation studies J Org Chem 38 1344 1348 10.1021/jo00947a020 1:CAS:528:DyaE3sXhtlGrsbs%3D
35. GJ Stevens K Hitchcock YK Wang GM Coppola RW Versace JA Chin M Shapiro S Suwanrumpha BL Mangold 1997 In vitro metabolism of N-(5-chloro-2-methylphenyl)- N'-(2-methylpropyl)thiourea: species comparison and identification of a novel thiocarbamide-glutathione adduct Chem Res Toxicol 10 733 741 10.1021/tx9700230 1:CAS:528:DyaK2sXktVSis74%3D
36. T Wang K Shankar MJ Ronis HM Mehendale 2000 Potentiation of thioacetamide liver injury in diabetic rats is due to induced CYP2E1 J Pharmacol Exp Ther 294 473 479 1:CAS:528:DC%2BD3cXltlKgs7g%3D
37. T Ji K Ikehata YM Koen SW Esch TD Williams RP Hanzlik 2007 Covalent modification of microsomal lipids by thiobenzamide metabolites in vivo Chem Res Toxicol 20 701 708 10.1021/tx600362h 1:CAS:528:DC%2BD2sXjtlCltb8%3D
38. Smith DA, van de Waterbeemd H, Walker DK (2001) In: Mannhold R, Kubinui H, Timmerman H (eds) Pharmacokinetics and metabolism in drug design, 1st edn. Weinheim, Wiley-VCH
39. Parkinson A, Ogilvie B (2008) In: Klaassen CD (ed) Casarett & doull's toxicology: the basic science of poisons, 7th edn. New York, McGraw-Hill